EMA Recommends Extension of Indications for Inotuzumab Ozogamicin By Ogkologos - April 29, 2026 185 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 8-Year-Old Cancer Survivor Celebrates Recovery By Donating Her Birthday Gifts To... July 23, 2019 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... August 8, 2022 Load more HOT NEWS FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers No Improvement in OS or PFS from Sacituzumab Govitecan Compared with... FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-mutated Metastatic...
